Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer

Partridge, Ann H.; Ruddy, Kathryn J.; Gelber, Shari; Schapira, Lidia; Abusief, Mary E.; Meyer, Meghan E.; Ginsburg, Elizabeth S.

doi:10.1016/j.fertnstert.2009.03.045

Cited by 183 publications

(132 citation statements)

References 29 publications

Supporting

Mentioning

116

Contrasting

Unclassified

Order By: Relevance

“…AMH seems to be uninfluenced by the hormonal status of patients, but, the Partridge et al (2010) and Anderson & Cameron (2011) studies suggest a possible role of hormonal treatment in changing levels of AMH compared with baseline. Wider clinical records could confirm or refute these data.…”

Section: Discussionmentioning

confidence: 99%

“…This study demonstrated that premenopausal breast cancer survivors have diminished ovarian reserve compared with controls. Interestingly, survivors receiving tamoxifen had lower AFC, AMH, inhibin B levels and higher E 2 levels than non-tamoxifen-treated survivors (Partridge et al 2010).…”

Section: Amh Chemo-induced Gonadal Damage and Adjuvant Therapy For mentioning

confidence: 92%

“…The authors' conclusion was that the AMH level before adjuvant chemotherapy predicts long-term ovarian function (Anderson & Cameron 2011). Partridge et al (2010) compared markers of ovarian reserve between 20 survivors of breast cancer exposed to cytotoxic chemotherapy (50% received tamoxifen) and 20 matched controls in a cross-sectional evaluation. This study demonstrated that premenopausal breast cancer survivors have diminished ovarian reserve compared with controls.…”

Section: Amh Chemo-induced Gonadal Damage and Adjuvant Therapy For mentioning

confidence: 99%

See 2 more Smart Citations

Anti-Müllerian hormone: determination of ovarian reserve in early breast cancer patients

Bozza¹,

Puglisi²,

Lambertini³

et al. 2013

Endocrine-Related Cancer

View full text Add to dashboard Cite

Breast cancer is the most common invasive cancer in women of reproductive age. In young women, chemotherapy may induce amenorrhea: it is still uncertain how to assess menopausal status in these patients despite the importance of its definition for choosing appropriate endocrine treatment. In the development of sensitive biomarkers for fertility and ovarian reserve, anti-Mü llerian hormone (AMH) is considered a promising marker of ovarian reserve. The clearest data regarding a clinical use of AMH are related to the measurement of the ovarian pool in women who undergo IVF: the available data, also in breast cancer patients, seem to suggest that AMH measurement, before gonadotropin administration, can be a useful marker for the prediction of women at risk for poor-response or no response to ovarian stimulation. The utility of AMH as a potential marker of chemotherapy-induced ovarian follicular depletion and an early plasma marker of chemotherapy-induced gonadal damage has been evaluated both in young women after treatment for cancer in childhood and in young survivors of hematological malignancies and solid tumors. Several studies have demonstrated a potential utility of AMH, inhibin, or follicle-stimulating factor as biomarkers predicting infertility risk in breast cancer patients, but the studies conducted so far are not conclusive. Further studies are needed in order to define the regimen-specific action of chemotherapy on AMH levels, the percentage of post-treatment recovery of plasma levels of the hormone, and the relationship between menopausal status and AMH.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Amh Chemo-induced Gonadal Damage and Adjuvant Therapy For mentioning

confidence: 92%

Section: Amh Chemo-induced Gonadal Damage and Adjuvant Therapy For mentioning

confidence: 99%

See 1 more Smart Citation

Anti-Müllerian hormone: determination of ovarian reserve in early breast cancer patients

Bozza¹,

Puglisi²,

Lambertini³

et al. 2013

Endocrine-Related Cancer

View full text Add to dashboard Cite

show abstract

“…Several other markers of ovarian reserve have been evaluated including early follicular phase serum E2, FSH, AMH and inhibin-B as well as measurements of antral follicle count (AFC) and ovarian volume. The interesting study of Partridge et al Partridge et al (2010) confirms that young breast cancer survivors who have undergone cytotoxic chemotherapy and remain premenopausal have diminished AFC levels when compared with healthy controls. This study also reveals that a lower level of AMH appears to be the best serum predictor of diminished AFC Partridge et al (2008;, which is thought to reflect reduced likelihood of future pregnancy.…”

Section: Assessing Post-chemotherapy Ovarian Functionmentioning

confidence: 90%

“…Some studies exhibit interesting results Anderson & Cameron (2011);Domingues et al (2010); Knauff et al (2009);Rosendahl et al (2010);Yu et al (2010). In the study of Partridge et al (2010), AFC and AMH seem to be the best markers of ovarian reserve. These two markers are highly correlated and for breast cancer patients receiving tamoxifen, lower AFC, AMH and inhibin-B were observed than for non-tamoxifen-treated survivors.…”

Section: Assessing Post-chemotherapy Ovarian Functionmentioning

confidence: 97%

Chemotherapy-Related Amenorrhea in Breast Cancer: Review of the Main Published Studies, Biomarkers of Ovarian Function and Mechanisms Involved in Ovarian Toxicity

Berlière¹,

Duhoux²,

Galant³

et al. 2011

Amenorrhea

View full text Add to dashboard Cite

Reducing the Long-term Effects of Chemotherapy in Young Women With Early-Stage Breast Cancer

Rugo¹,

Rosen²

2011

JAMA

View full text Add to dashboard Cite

A LTHOUGH THE MEDIAN AGE OF WOMEN DIAGnosed with breast cancer is 61 years, about 35% of women newly diagnosed with breast cancer are 54 years or younger, and 12%-almost 25 000-are younger than 45 years.1 The majority of women with breast cancer will receive adjuvant therapy including chemotherapy, hormone therapy, or both, which has been documented to improve disease-free and overall survival. Treatment has a number of adverse effects that directly affect short-term and, in some cases, long-term quality of life. For young women of childbearing age, one of the most devastating adverse effects involves the prospect of loss of fertility, and this concern may influence choice of therapy and adherence to a prescribed treatment plan.2 For some women, concern about early menopause is paramount.Chemotherapy agents exert toxicity in the ovary by causing apoptotic oocyte death in primordial follicles, damaging ovarian reserve and interrupting follicle recruitment and maturation.3 Almost all women develop at least temporary chemotherapy-induced amenorrhea. Reports have suggested a wide range of permanent amenorrhea rates following adjuvant chemotherapy, with important variables including age, treatment regimen, and use of tamoxifen. Historically, the risk of permanent amenorrhea in women younger than 40 years with earlystage breast cancer following adjuvant chemotherapy was reported to be about 40%, compared with 76% in older women. 4 Alkylating agents, particularly the combination regimen of oral CMF (cyclophosphamide, methotrexate, and fluorouracil), are associated with the highest risk of ovarian failure, reaching 90% in women older than 40 years. 4 Current chemotherapy regimens generally have less ovarian toxicity, with significantly lower rates of permanent amenorrhea. Although recovery of menses is still closely related to the variables listed above, in one report 85% of women aged 40 years or younger treated with adjuvant anthracycline and taxane-based chemotherapy recovered menses within 1 year, 5 with docetaxel regimens resulting in higher rates of prolonged amenorrhea.

show abstract

Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer

Cited by 183 publications

References 29 publications

Anti-Müllerian hormone: determination of ovarian reserve in early breast cancer patients

Anti-Müllerian hormone: determination of ovarian reserve in early breast cancer patients

Chemotherapy-Related Amenorrhea in Breast Cancer: Review of the Main Published Studies, Biomarkers of Ovarian Function and Mechanisms Involved in Ovarian Toxicity

Reducing the Long-term Effects of Chemotherapy in Young Women With Early-Stage Breast Cancer

Contact Info

Product

Resources

About